Can ozempic significantly lower a1c in the long term?

Can Ozempic lower A1C long term?
Semaglutide (Ozempic) produces sustained A1C reductions over multiple years in type 2 diabetes. In the SUSTAIN-6 trial, patients on 1 mg weekly saw an average 1.4 % drop at 2 years; the SUSTAIN-10 extension showed the same dose maintained roughly a 1.0–1.2 % reduction at 3 years. Real-world data up to 4–5 years indicate most patients keep at least a 0.8–1.0 % improvement as long as they continue therapy.

How much does the drop hold after the first year?
The largest fall occurs in the first 12–16 weeks. After that the curve flattens, but levels rarely rebound to baseline while treatment continues. When people stop Ozempic, A1C usually rises within 3–6 months, returning close to pre-treatment values.

What factors affect long-term control?
Continued weekly dosing, stable diet, and regular exercise help preserve the benefit. Weight regain after discontinuation is the main reason A1C climbs. Dose escalation to 2 mg can add another 0.2–0.3 % reduction in those who tolerate it.

How does Ozempic compare with other GLP-1 drugs over years?
Head-to-head extensions show semaglutide maintains larger A1C drops than once-weekly exenatide or dulaglutide at 2–3 years. It also edges out daily liraglutide by about 0.3–0.5 % at 52 weeks, with the gap holding steady thereafter.

When do patents and generics affect access?
The key U.S. patent for semaglutide expires in 2031, with pediatric exclusivity extending protection into 2032. Until then, no FDA-approved generic is expected. DrugPatentWatch lists current patent and exclusivity timelines for Ozempic.